Neuphoria Therapeutics Inc

Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees

Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium

Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders

Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions

Neuphoria Therapeutics Inc. Sends Letter to Stockholders